Preliminary analysis on graft failure after non-T-cell depleted haploidentical hematopoietic stem cell transplantation
10.3969/j.issn.1006-5725.2016.20.033
- VernacularTitle:非去T细胞半相合造血干细胞移植术后植入失败的初步分析
- Author:
Bin GU
;
Guanghua CHEN
;
Xiao MA
;
Chengcheng FU
;
Yue HAN
;
Xiaowen TANG
;
Zhengming JIN
;
Miao MIAO
;
Huiying QIU
;
Aining SUN
;
Depei WU
- Publication Type:Journal Article
- Keywords:
Non-T-cell depleted;
Haploidentical hematopoietic stem cell transplantation;
Graft failure
- From:
The Journal of Practical Medicine
2016;32(20):3401-3404
- CountryChina
- Language:Chinese
-
Abstract:
Objective To summarize the clinical features of graft failure (GF)after non-T-cell depleted haploidentical hematopoietic stem cell transplantation (Haplo-HCT), and to investigate the causes and treatment. Methods A retrospective analysis was carried out on 174 patientswho accepted the non-T-cell depleted Haplo-HCT from Jan 2012 to Dec 2013. The patients′ donor specific anti human leukocyte antigen antibodies (DSA) from the peripheral blood serum were detected and those DSA positive patients were treated by immunoglobulin or plasma exchange before transplatation. Results A total of three patients with acute myeloid leukemia got GF, the incidence rate was 1.72%. The patient with primary GF was given a secondHaplo-HCT, but did not get implanted with leukemia remission and three lineages persistently low , he was died of pulmonary infection eight monthes after the second transplant. One of the secondary GF patients was given peripheral blood mononuclear cells(PBMNCs) mobilized by granulocyte colony stimulating factor (G-CSF) from the donor, and got full donor chimerism on day 16 after infusion. The disease-free survival has been for 18 months. The other case was found that DSA was positive, the mean fluorescence intensity (MFI) value was 15000, then Rituximab and PBMNCs mobilized by G-CSF were administrated successively. On day 14 after infusion the partient got full donor chimerism , and MFI turned negative. The patient has been disease-free survival for 41 months. Conclusion Graft failure is a rare but fatal complication after non-T-cell depletedHaplo-HCT, Rituximab followed by PBMNCs are effective measures for DSA related GF, as were worthy of further study.
